3.6608
price down icon6.85%   -0.2692
after-market Handel nachbörslich: 3.66 -0.0008 -0.02%
loading
Schlusskurs vom Vortag:
$3.93
Offen:
$3.85
24-Stunden-Volumen:
5,725
Relative Volume:
0.15
Marktkapitalisierung:
$3.42M
Einnahmen:
$61,000
Nettoeinkommen (Verlust:
$-5.46M
KGV:
-0.5598
EPS:
-6.54
Netto-Cashflow:
$-6.76M
1W Leistung:
-0.52%
1M Leistung:
-9.61%
6M Leistung:
-30.93%
1J Leistung:
-46.87%
1-Tages-Spanne:
Value
$3.59
$3.85
1-Wochen-Bereich:
Value
$3.48
$4.1481
52-Wochen-Spanne:
Value
$3.03
$14.80

Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile

Name
Firmenname
Titan Pharmaceuticals Inc De
Name
Telefon
(650) 244-4990
Name
Adresse
400 OYSTER POINT BLVD, SAN FRANCISCO
Name
Mitarbeiter
4
Name
Twitter
@titanpharma
Name
Nächster Verdiensttermin
2024-06-28
Name
Neueste SEC-Einreichungen
Name
TTNP's Discussions on Twitter

Vergleichen Sie TTNP mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TTNP
Titan Pharmaceuticals Inc De
3.6608 3.42M 61,000 -5.46M -6.76M -6.54
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 65.79B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 35.18B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 32.67B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 26.46B 3.81B -644.79M -669.77M -6.24

Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2019-06-26 Eingeleitet Maxim Group Buy
2017-11-10 Herabstufung ROTH Capital Buy → Neutral

Titan Pharmaceuticals Inc De Aktie (TTNP) Neueste Nachrichten

pulisher
08:05 AM

Rigel Strengthens Biotech Team: Strategic Stock Grants Attract Key Talent - Stock Titan

08:05 AM
pulisher
Mar 31, 2025

NRx Pharmaceuticals Lands Revenue-Generating Mental Health Clinic in Strategic Veterans Care Push - Stock Titan

Mar 31, 2025
pulisher
Mar 23, 2025

$10M Capital Raise: TransCode Therapeutics Accelerates TTX-MC138 Clinical Trials - StockTitan

Mar 23, 2025
pulisher
Mar 21, 2025

Titan Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post

Mar 21, 2025
pulisher
Mar 20, 2025

Major Shake-up: Universe Pharmaceuticals Announces 40:1 Share ConsolidationWhat It Means For Investors - StockTitan

Mar 20, 2025
pulisher
Mar 19, 2025

Generic Drug Alert: ANI Pharmaceuticals Takes On $36M Market With New Alinia Alternative - StockTitan

Mar 19, 2025
pulisher
Mar 13, 2025

Shuttle Pharma Raises $5.75M: Strategic Boost for Revolutionary Cancer Treatment Trial - Stock Titan

Mar 13, 2025
pulisher
Mar 12, 2025

Leading Radiotherapy Company Actinium Opens Exclusive Investor Access at ROTH 2025 - Stock Titan

Mar 12, 2025
pulisher
Mar 11, 2025

Endo's $99M Strategic Sale: International Pharma Division Goes to Knight Therapeutics - Stock Titan

Mar 11, 2025
pulisher
Mar 10, 2025

Acurx Raises $1.1M in Direct Offering to Advance Antibiotics Pipeline - StockTitan

Mar 10, 2025
pulisher
Mar 07, 2025

Can This $1.1M Funding Keep Acurx's Antibiotic Development on Track? - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Will NovaBay Survive? Crucial Stockholder Vote Could Determine Company's Fate - StockTitan

Mar 07, 2025
pulisher
Mar 06, 2025

Can Conduit Pharmaceuticals Keep Its Nasdaq Listing? Critical Deadlines Ahead - Stock Titan

Mar 06, 2025
pulisher
Mar 05, 2025

How Will CTT Pharmaceuticals' OTCQB Upgrade Transform Its Market Presence? - StockTitan

Mar 05, 2025
pulisher
Mar 05, 2025

Will Amphastar Reveal New Strategic Insights at Upcoming Barclays Healthcare Conference? - Stock Titan

Mar 05, 2025
pulisher
Mar 04, 2025

Milestone Pharmaceuticals Awards 94,000 Stock OptionsWhat This Means for Shareholder Value - Stock Titan

Mar 04, 2025
pulisher
Mar 03, 2025

Elite Pharmaceuticals Triples Manufacturing Potential With High-Speed Facility Launch - StockTitan

Mar 03, 2025
pulisher
Feb 28, 2025

Is Vincerx Pharma Running Out of Options? Merger Deal Collapses as Cash Dwindles - Stock Titan

Feb 28, 2025
pulisher
Feb 27, 2025

Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan

Feb 27, 2025
pulisher
Feb 27, 2025

When Can Investors Hear Milestone Pharma's Next Strategic Update? Key Conference Date Revealed - Stock Titan

Feb 27, 2025
pulisher
Feb 26, 2025

Can CNS Pharmaceuticals' $14M War Chest Deliver on Its Promising Brain Cancer Treatment? - StockTitan

Feb 26, 2025
pulisher
Feb 25, 2025

Will Universe Pharmaceuticals Survive Nasdaq's Latest Delisting Threat? - StockTitan

Feb 25, 2025
pulisher
Feb 24, 2025

Can Phathom's VOQUEZNA Sales Drive Q4 Growth? Earnings Call Set for March 6 - Stock Titan

Feb 24, 2025
pulisher
Feb 21, 2025

Will SXTC's Share Consolidation Save Its Nasdaq Listing? Key Dates Revealed - StockTitan

Feb 21, 2025
pulisher
Feb 20, 2025

Can This $430M Pharma Merger Create the Next Women's Health Giant? - StockTitan

Feb 20, 2025
pulisher
Feb 20, 2025

Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - Stock Titan

Feb 19, 2025
pulisher
Feb 18, 2025

Major Capital Raise: Petros Pharmaceuticals Locks $9.6M Financing DealStrategic Move or Dilution Risk? - Stock Titan

Feb 18, 2025
pulisher
Feb 14, 2025

Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M - StockTitan

Feb 14, 2025
pulisher
Feb 13, 2025

Elite Pharma Q3 Results Reveal Sharp Profit Decline: Holiday Delays Impact Performance - StockTitan

Feb 13, 2025
pulisher
Feb 13, 2025

Major Lupus Breakthrough? Conduit Teams Up with Charles River for Game-Changing Treatment Study - Stock Titan

Feb 13, 2025
pulisher
Feb 11, 2025

Milestone's CARDAMYST Launch Roadmap: Key Details Coming for $1B PSVT Market Opportunity - Stock Titan

Feb 11, 2025
pulisher
Feb 10, 2025

Elite Pharmaceuticals (ELTP) Earnings Preview: Q3 Performance & Strategic Roadmap Unveiling Feb 14 - StockTitan

Feb 10, 2025
pulisher
Feb 10, 2025

Opioid Use Disorders Market to Reach USD 8.8 Billion by - GlobeNewswire

Feb 10, 2025
pulisher
Feb 07, 2025

Critical Safety Signal Emerges: Pliant's IPF Drug Trial Faces Unexpected DSMB Intervention - StockTitan

Feb 07, 2025
pulisher
Feb 07, 2025

Breakthrough NPC1 Treatment Data: 87% of Young Patients Show Recovery Signs in Cyclo Trial - StockTitan

Feb 07, 2025
pulisher
Feb 07, 2025

Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan

Feb 07, 2025
pulisher
Feb 06, 2025

TFF Pharmaceuticals to Exit Nasdaq: Complete Liquidation Plan Leaves Shareholders in Limbo - StockTitan

Feb 06, 2025
pulisher
Feb 06, 2025

Major Biotech Conferences Alert: NRx Pharmaceuticals Sets Stage for Key Industry Updates - StockTitan

Feb 06, 2025
pulisher
Feb 05, 2025

Oncology & Obesity Pipeline Update: Terns Pharmaceuticals Takes Center Stage at Major Healthcare Conference - StockTitan

Feb 05, 2025
pulisher
Feb 04, 2025

Inside Apellis' Strategic Move: New Talent Secured with 7,805 RSU Compensation Package - StockTitan

Feb 04, 2025
pulisher
Feb 04, 2025

KalVista Pharmaceutical's Major Talent Push: 261,000 Stock Options Awarded in Strategic Growth Move - StockTitan

Feb 04, 2025
pulisher
Feb 04, 2025

Cumberland's DMD Heart Disease Drug Shows Breakthrough 5.4% LVEF Improvement in Phase 2 | CPIX Stock News - Stock Titan

Feb 04, 2025
pulisher
Feb 03, 2025

Nasdaq Delisting Drama: Universe Pharmaceuticals Given 7 Days to Save Its Listing - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

X4 Pharma's Latest Employee Stock Plan: Strategic Move to Attract Top Talent - StockTitan

Feb 03, 2025
pulisher
Feb 03, 2025

Mental Health Revolution: HOPE's $27M Backed Ketamine Clinic Network Takes Shape With BTIG Partnership - StockTitan

Feb 03, 2025
pulisher
Jan 30, 2025

Virpax Secures Critical $6M Funding: What This Means for Probudur's Future - StockTitan

Jan 30, 2025
pulisher
Jan 29, 2025

Major Setback: CARGO's Cancer Treatment Shows Alarming Safety Issues, Forces Company Restructure - StockTitan

Jan 29, 2025
pulisher
Jan 28, 2025

Virpax Secures Critical $6M Funding: Game-Changing Move for Probudur Development - StockTitan

Jan 28, 2025
pulisher
Jan 28, 2025

Revolutionary Mental Health Company Plans 100M Revenue Push with Ketamine Clinics - StockTitan

Jan 28, 2025
pulisher
Jan 28, 2025

NRx Pharma's $8.9M Deal Unlocks Path to FDA Approval for Revolutionary Depression Treatments - StockTitan

Jan 28, 2025

Finanzdaten der Titan Pharmaceuticals Inc De-Aktie (TTNP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.26
price down icon 10.70%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):